GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis.
作者信息
Speca Silvia, Dubuquoy Caroline, Rousseaux Christel, Chavatte Philippe, Desreumaux Pierre, Spagnolo Paolo
机构信息
The University of Lille, INSERM, U1286 - Infinite - Institute for Translational Research in Inflammation, Lille, France.
Intestinal Biotech Development, Lille, France.
出版信息
Cell Mol Immunol. 2020 Dec;17(12):1272-1274. doi: 10.1038/s41423-020-0394-y. Epub 2020 Mar 12.
Abstract
摘要
相似文献
1
GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis.GED-0507是一种用于治疗肺纤维化的新型潜在抗纤维化治疗选择。
Cell Mol Immunol. 2020 Dec;17(12):1272-1274. doi: 10.1038/s41423-020-0394-y. Epub 2020 Mar 12.
2
Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication.用于肺结节病的抗纤维化药物：寻找适应证的一种治疗方法。
Respir Med. 2021 Apr-May;180:106371. doi: 10.1016/j.rmed.2021.106371. Epub 2021 Mar 22.
3
GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro.GED-0507 通过在体内和体外拮抗肌成纤维细胞转分化来减轻肺纤维化。
PLoS One. 2021 Sep 16;16(9):e0257281. doi: 10.1371/journal.pone.0257281. eCollection 2021.
4
Preclinical studies of a specific PPARγ modulator in the control of skin inflammation.一种特定的过氧化物酶体增殖物激活受体 γ 调节剂在皮肤炎症控制中的临床前研究。
J Invest Dermatol. 2014 Apr;134(4):1001-1011. doi: 10.1038/jid.2013.448. Epub 2013 Oct 28.
5
COVID-related fibrosis: insights into potential drug targets.COVID 相关纤维化：潜在药物靶点的新见解。
Expert Opin Investig Drugs. 2021 Dec;30(12):1183-1195. doi: 10.1080/13543784.2021.2010188. Epub 2021 Dec 1.
6
Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis.新型PPARγ调节剂GED-0507-34左旋体可改善炎症驱动的肠道纤维化。
Inflamm Bowel Dis. 2016 Feb;22(2):279-92. doi: 10.1097/MIB.0000000000000618.
7
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.阿九酸在博来霉素诱导的肺纤维化形成阶段发挥强大的抗纤维化作用。
Respir Res. 2016 May 6;17(1):49. doi: 10.1186/s12931-016-0373-0.
8
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?博来霉素动物模型：一种用于研究特发性肺纤维化治疗方案的有用工具？
Int J Biochem Cell Biol. 2008;40(3):362-82. doi: 10.1016/j.biocel.2007.08.011. Epub 2007 Aug 30.
9
Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.新型松弛素样活性抗纤维化肽预防博来霉素诱导的肺纤维化。
J Pharmacol Exp Ther. 2010 Dec;335(3):589-99. doi: 10.1124/jpet.110.170977. Epub 2010 Sep 8.
10
Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis.糖原合酶激酶-3β和过氧化物酶体增殖物激活受体-γ在葡聚糖硫酸钠诱导的结肠纤维化上皮-间质转化中的作用
PLoS One. 2017 Feb 16;12(2):e0171093. doi: 10.1371/journal.pone.0171093. eCollection 2017.
引用本文的文献
1
Macrophage-targeted delivery of siRNA to silence gene expression attenuates pulmonary fibrosis.靶向巨噬细胞递送小干扰RNA以沉默基因表达可减轻肺纤维化。
Bioeng Transl Med. 2022 Jan 18;7(2):e10280. doi: 10.1002/btm2.10280. eCollection 2022 May.
2
The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.甲基化 CpG 结合域 2 通过协调成纤维细胞向肌成纤维细胞分化来促进肺纤维化。
Eur Respir J. 2022 Sep 29;60(3). doi: 10.1183/13993003.03697-2020. Print 2022 Sep.
3
GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro.GED-0507 通过在体内和体外拮抗肌成纤维细胞转分化来减轻肺纤维化。
PLoS One. 2021 Sep 16;16(9):e0257281. doi: 10.1371/journal.pone.0257281. eCollection 2021.
4
The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders.上皮-间质转化作为纤维化疾病潜在的治疗靶点
Front Cell Dev Biol. 2020 Dec 21;8:607483. doi: 10.3389/fcell.2020.607483. eCollection 2020.
Zotero 插件